Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FullHope Biomedical CoROCO:7773 -4.80%14 PS Ratio is 24.50 as of Jul. 19, 2026, which is 63% below its 10-year median of 65.35. GuruFocus rates ROCO:7773 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 931 Biotechnology companies, FullHope Biomedical Co ranks worse than 70.57% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, FullHope Biomedical Co's share price is NT$26.75.
FullHope Biomedical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.09. Hence, FullHope Biomedical Co's PS Ratio for today is 24.50.
The historical rank and industry rank for FullHope Biomedical Co's PS Ratio or its related term are showing as below:
ROCO:7773'
s PS Ratio Range Over the Past 10 Years
Min: 21.06 Med: 65.35 Max: 97.13
Current: 24.5
During the past 5 years, FullHope Biomedical Co's highest PS Ratio was 97.13. The lowest was 21.06. And the median was 65.35.
ROCO:7773's PS Ratio is ranked worse than 70.57% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs ROCO:7773: 24.50
During the past 5 years, FullHope Biomedical Co's highest 3-Year average Revenue per Share Growth Rate was 23.30% per year. The lowest was 23.30% per year. And the median was 23.30% per year.
Back to Basics: PS Ratio
FullHope Biomedical Co (ROCO:7773) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7773 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, FullHope Biomedical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FullHope Biomedical Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, FullHope Biomedical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where FullHope Biomedical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
FullHope Biomedical Co's Share Price of today is NT$26.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. FullHope Biomedical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
FullHope Biomedical Co (ROCO:7773) has a PS Ratio of 24.50 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on FullHope Biomedical Co and its competitors. This is 63% below median its historical median of 65.35. Over the past decade, FullHope Biomedical Co's PS Ratio has ranged from 21.06 to 97.13. According to the industry distribution chart, FullHope Biomedical Co ranks #657 out of 931 companies in the Biotechnology industry, placing it in the top 70.6%.
Is FullHope Biomedical Co's PS Ratio too high?
FullHope Biomedical Co's current PS Ratio of 24.50 is 63% below median its 10-year median of 65.35. Over the past 10 years, this metric has ranged from a low of 21.06 to a high of 97.13. The Biotechnology industry median PS Ratio is 9.32. FullHope Biomedical Co's value of 24.50 is 162.9% above this industry median. Based on the distribution chart, FullHope Biomedical Co ranks #657 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, FullHope Biomedical Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, FullHope Biomedical Co ranks #657 out of 931 companies for PS Ratio. This places FullHope Biomedical Co in the lower half of its industry. The industry median PS Ratio is 9.32. FullHope Biomedical Co's value of 24.50 is 162.9% above this benchmark. Historically, FullHope Biomedical Co's own PS Ratio has ranged from 21.06 to 97.13 over the past decade. While the company's 10-year median is 65.35 vs. the industry median of 9.32, FullHope Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. FullHope Biomedical Co's current PS Ratio of 24.50 is 162.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on FullHope Biomedical Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. FullHope Biomedical Co's current PS Ratio is 24.50, which is 63% below median its own 10-year median of 65.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current PS Ratio of 24.50. The current PS Ratio is 24.50, which is 63% below median its 10-year median of 65.35 and 162.9% above the Biotechnology industry median of 9.32. FullHope Biomedical Co's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current PS Ratio is 24.50 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
14GF Score
Get the complete analysis for ROCO:7773
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7773 has been successfully added to your 
